FDA Approves Insulin Glargine as Country’s First generic

  The U.S. Food and Drug Administration approved the first  interchangeable biosimilar insulin product, indicated to improve  glycemic control in adults and pediatric patients with Type 1 diabetes  mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin  glargine-yfgn) is both biosimilar to, and interchangeable with (can be  substituted for), its reference product Lantus (insulin glargine), a  long-acting insulin analog. Semglee (insulin glargine-yfgn) as the first generic insulin

 Walmart announced it is launching its own private brand of insulin, which the  big box chain says will save customers with diabetes up to 75% on the  lifesaving drug. 

 Too many people with diabetes are still unaware of modern diabetes  measurement tools, such as time in range. We want to change that.  

Erin Black of CNBC and also a type 1 diabetic herself, speaks to physicians and others in the diabetes community why people with diabetes are a higher risk of complications if they become infected with Covid 19.

San Francisco, California, June 12, 2019 - This year's American Diabetes Association Scientific Sessions held in San Francisco definitely had more of an energetic buzz and air of anticipation than the past few years, if you ask us.

This is most certainly due to the incredible progress in new Artificial Pancreas (aka Closed Loop or Automated Insulin Delivery) systems coming soon, along with better CGM sensors, infusion devices and apps. Not to mention new smart insulin click here to read more